Next-generation conjugates: small peptides to transform targeted cancer therapy
Bioconjugation Insights · 2025
DOI: 10.18609/bci.2025.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugation Insights, 2025. Verfasst von Michelle Morrow. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“Our mission is to extend the therapeutic index of toxic payloads that effectively target cancer.”Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Michelle Morrow, Chief Scientific Officer, Avacta, about a novel drug delivery platform that utilizes a small peptide with a capping group conjugated to a cytotoxic cancer drug. She discusses the advantages of the platform over traditional ADC therapies including the improved precision and safety of cancer treatment.Bioconjugation Insights is the only dedicated provider of specialized, high-quality, Open Access digital content tailored to the bioconjugation field. To read more of our Open Access content, please register here.
Zitieren
APA
Morrow, M. (2025). Next-generation conjugates: small peptides to transform targeted cancer therapy. Bioconjugation Insights. https://doi.org/10.18609/bci.2025.002
Vancouver
Morrow M. Next-generation conjugates: small peptides to transform targeted cancer therapy. Bioconjugation Insights. 2025. doi:10.18609/bci.2025.002
BibTeX
@article{Morrow2025,
author = {Morrow, Michelle},
title = {Next-generation conjugates: small peptides to transform targeted cancer therapy},
journal = {Bioconjugation Insights},
year = {2025},
doi = {10.18609/bci.2025.002}
}
EUVIMED